BRPI0520610A2 - formulação de comprimido de medicamento para alìvio de dor - Google Patents

formulação de comprimido de medicamento para alìvio de dor

Info

Publication number
BRPI0520610A2
BRPI0520610A2 BRPI0520610-3A BRPI0520610A BRPI0520610A2 BR PI0520610 A2 BRPI0520610 A2 BR PI0520610A2 BR PI0520610 A BRPI0520610 A BR PI0520610A BR PI0520610 A2 BRPI0520610 A2 BR PI0520610A2
Authority
BR
Brazil
Prior art keywords
medicament
dust
pain relief
tablet formulation
formulation
Prior art date
Application number
BRPI0520610-3A
Other languages
English (en)
Inventor
Louis Cartilier
Mihaela Ungur
Chafic Chebli
Original Assignee
Univ Montreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Montreal filed Critical Univ Montreal
Publication of BRPI0520610A2 publication Critical patent/BRPI0520610A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

FORMULAçãO DE COMPRIMIDO DE MEDICAMENTO PARA ALìVIO DE DOR. Uma formulação de comprimido para alivio de dor para a administração oral de um medicamento o qual é feito de uma combinação comprimida de ao menos três pós ou polvilhos secos incluindo um pó ou polvilho de um medicamento; um pó ou polvilho de uma matriz para a liberação do medicamento de alívio; e um pó ou polvilho de ao menos um eletrólito. A matriz de liberação do medicamento de alívio consistindo de um amido de alta amilose não ligado transversalmente, onde o amido de alta amilose é substituído por ao menos um substituinte orgânico compreendendo de ao menos um grupo carboxila. O substituinte orgânico é preferivelmente uma carboxialquila tendo de 2 à 4 átomos de carbono, seus sais ou a mistura dos mesmos. Esse comprimido tem a vantagem de ter uma aperfeiçoada integridade.
BRPI0520610-3A 2004-12-24 2005-12-20 formulação de comprimido de medicamento para alìvio de dor BRPI0520610A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002491665A CA2491665A1 (fr) 2004-12-24 2004-12-24 Formulation de comprime pour liberation soutenue de principe actif
PCT/CA2005/001934 WO2006066399A1 (en) 2004-12-24 2005-12-20 Tablet formulation for sustained drug-release

Publications (1)

Publication Number Publication Date
BRPI0520610A2 true BRPI0520610A2 (pt) 2009-10-06

Family

ID=36601318

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0520610-3A BRPI0520610A2 (pt) 2004-12-24 2005-12-20 formulação de comprimido de medicamento para alìvio de dor

Country Status (10)

Country Link
US (1) US20090011014A1 (pt)
EP (1) EP1833468A1 (pt)
JP (1) JP2008525322A (pt)
KR (1) KR20070094009A (pt)
CN (1) CN101087595A (pt)
AU (1) AU2005318827A1 (pt)
BR (1) BRPI0520610A2 (pt)
CA (1) CA2491665A1 (pt)
IL (1) IL184067A0 (pt)
WO (1) WO2006066399A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5547966B2 (ja) * 2006-12-15 2014-07-16 カンピナ ネーデルランド ホールディング ビー．ブイ． 持続放出用の賦形剤及びその使用
EP1935411A1 (en) 2006-12-15 2008-06-25 Campina Nederland Holding B.V. Slow release excipient and its use
CA2590821A1 (en) * 2007-06-07 2008-12-07 Universite De Montreal High-amylose sodium carboxymethyl starch sustained release excipient and process for preparing the same
EP2415460A1 (de) * 2010-08-03 2012-02-08 ratiopharm GmbH Orale Darreichungsform von Pregabalin
US20130338121A1 (en) * 2011-03-01 2013-12-19 Le Tien Canh Two speed monolithic system for controlled release of drugs
CN103305748A (zh) 2012-03-15 2013-09-18 宝山钢铁股份有限公司 一种无取向电工钢板及其制造方法
GB201622024D0 (en) 2016-11-14 2017-02-08 Inventage Lab Inc Apparatus and method for large scale production of monodisperse, microsheric and biodegradable polymer-based drug delivery
KR20200013170A (ko) 2018-07-20 2020-02-06 주식회사 코아팜바이오 약물 방출 제어 구조를 포함하는 정제 및 3d 프린트 기술을 이용한 정제 제조방법
CN111198246B (zh) * 2018-11-19 2022-07-15 上海梅山钢铁股份有限公司 一种烧结脱硫脱硝灰中碳酸钙含量的检测方法
CN110200947A (zh) * 2019-06-27 2019-09-06 深圳市泛谷药业股份有限公司 一种安非他酮肠溶缓释微丸胶囊及其制备方法
CN115317459B (zh) * 2022-09-05 2023-10-31 安徽金太阳生化药业有限公司 一种氯霉素片的制备工艺

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3034911A (en) * 1959-03-25 1962-05-15 Nat Starch Chem Corp Tablet disintegrants
US3490742A (en) * 1966-01-14 1970-01-20 Staley Mfg Co A E Compressed tablets
US3622677A (en) * 1969-07-07 1971-11-23 Staley Mfg Co A E Compressed tablets containing compacted starch as binder-disintegrant ingredient
US4072535A (en) * 1970-12-28 1978-02-07 A. E. Staley Manufacturing Company Precompacted-starch binder-disintegrant-filler material for direct compression tablets and dry dosage capsules
US4369308A (en) * 1981-07-24 1983-01-18 National Starch And Chemical Corporation Low swelling starches as tablet disintegrants
US4904476A (en) * 1986-03-04 1990-02-27 American Home Products Corporation Formulations providing three distinct releases
GB8812490D0 (en) * 1988-05-26 1988-06-29 Agricultural & Food Res Delayed release formulations
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
US5468286A (en) * 1989-10-25 1995-11-21 National Starch And Chemical Investment Holding Corporation Enzymatically debranched starches as tablet excipients
EP0475482B1 (en) * 1990-09-13 1994-10-05 Akzo Nobel N.V. Stabilized solid chemical compositions
CA2041774C (en) * 1990-11-27 1994-04-19 Mircea A. Mateescu Use of cross-linked amylose as a matrix for the slow release of biologically active compounds
US5603956A (en) * 1990-11-27 1997-02-18 Labopharm Inc. Cross-linked enzymatically controlled drug release
US5616343A (en) * 1993-03-25 1997-04-01 Labopharm, Inc. Cross-linked amylose as a binder/disintegrant in tablets
JP4072597B2 (ja) * 1994-12-27 2008-04-09 ナムローゼ・フェンノートシャップ・オルガノン 持続性製剤
US5888534A (en) * 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
CA2173818A1 (fr) * 1996-04-10 1997-10-11 Francois Chouinard Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose
DE19640062B4 (de) * 1996-09-28 2006-04-27 Lts Lohmann Therapie-Systeme Ag Orale Zubereitung, enthaltend in einer in wässrigem Medium quellbaren Matrix wenigstens einen pharmazeutischen Wirkstoff
US5879707A (en) * 1996-10-30 1999-03-09 Universite De Montreal Substituted amylose as a matrix for sustained drug release
US5807575A (en) * 1997-02-14 1998-09-15 Rougier Inc. Manufacture of cross-linked amylose useful as a excipient for control release of active compounds
US6284273B1 (en) * 1998-02-24 2001-09-04 Vincent Lenaerts Cross-linked high amylose starch resistant to amylase as a matrix for the slow release of biologically active compounds
IT1318597B1 (it) * 2000-06-23 2003-08-27 A C R Applied Coating Res S A Uso di un amido ad alto contenuto di amilosio acetilato epregelatinizzato.
US6607748B1 (en) * 2000-06-29 2003-08-19 Vincent Lenaerts Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
MXPA05004410A (es) * 2002-10-25 2005-11-23 Labopharm Inc Composiciones de liberacion controlada.

Also Published As

Publication number Publication date
CA2491665A1 (fr) 2006-06-24
KR20070094009A (ko) 2007-09-19
EP1833468A1 (en) 2007-09-19
JP2008525322A (ja) 2008-07-17
AU2005318827A1 (en) 2006-06-29
US20090011014A1 (en) 2009-01-08
WO2006066399A1 (en) 2006-06-29
CN101087595A (zh) 2007-12-12
IL184067A0 (en) 2007-10-31

Similar Documents

Publication Publication Date Title
BR0014383A (pt) Composições de liberação controlada compreendendo nimesulida
BRPI0520610A2 (pt) formulação de comprimido de medicamento para alìvio de dor
Sekar et al. Immediate release tablets of telmisartan using superdisintegrant-formulation, evaluation and stability studies
HRP20130114T4 (hr) Farmaceutski oblik s brzim oslobađanjem sinakalcet hci
CO5190672A1 (es) Composicion para la dosificacion oral, de disolucion instantanea
Lee et al. Tramadol 37.5-mg/acetaminophen 325-mg combination tablets added to regular therapy for rheumatoid arthritis pain: a 1-week, randomized, double-blind, placebo-controlled trial
RU94032150A (ru) Лекарственное средство с замедленным высвобождением активно-действующего вещества
BR9913696A (pt) Sistema de liberação de drogas, administrado oralmente, proporcionando controle temporal e espacial
RU2007126652A (ru) Композиции и способы стабилизации активных фармацевтических ингредиентов
MX2008012731A (es) Tabletas de paracetamol de liberacion rapida.
BRPI0418026A (pt) derivados de fenilalanina ou sais farmaceuticamente aceitáveis destes, composição farmacêutica, antagonista de alfa4 integrina, e, agente terapêutico ou agente preventivo para doenças
BRPI0518266B8 (pt) medicamento oral de liberação modificada de pelo menos um princípio ativo sob a forma multimicrocapsular
JPS6388122A (ja) 吸収および作用が速やかなサリンダツクまたはサリンダツクナトリウムと塩基の併用剤
JP2007520506A5 (pt)
MA33463B1 (fr) Compositions à dose pharmaceutique solide fixe comprenant de l'irbésartan et de l'amlodipine, leur préparation et leur application thérapeutique
SE9901573D0 (sv) New compounds
BR0013719A (pt) Dosagem oral de liberaçâo controlada, apropriada para administração oral
ID28510A (id) Formulasi oral yang baru untuk agonis atau antagonis 5-ht4
RU2006104009A (ru) Фармацевтическая препаративная форма
BR0308305A (pt) Fórmulas dosadas de liberação controlada
JPH05246845A (ja) イブプロフェン含有解熱鎮痛剤
TWI630911B (zh) 包含異菸鹼醯胺（ｉｓｏｎｉａｚｉｄ）顆粒及利福噴丁（ｒｉｆａｐｅｎｔｉｎｅ）顆粒之可分散錠劑型態的抗肺結核穩定醫藥組合物及其製備方法
TR200103144T2 (tr) Yeni bileşikler
JP2019522030A5 (pt)
BRPI0408805A (pt) composição farmacêutica contendo complexo de platina e método de fabricação da mesma

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO EM SUA FORMA AUTENTICADA; OU SEGUNDO PARECER DA PROCURADORIA NO 074/93, DEVE CONSTAR UMA DECLARACAO DE VERACIDADE, A QUAL DEVE SER ASSINADA POR UMA PESSOA DEVIDAMENTE AUTORIZADA A REPRESENTAR O INTERESSADO, DEVENDO A MESMA CONSTAR NO INSTRUMENTO DE PROCURACAO, OU NO SEU SUBSTABELECIMENTO.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.